UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 23 von 111
Datensatz exportieren als...
BibTeX
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
American journal of hematology, 2017-01, Vol.92 (1), p.37-41
Polverelli, Nicola
Breccia, Massimo
Benevolo, Giulia
Martino, Bruno
Tieghi, Alessia
Latagliata, Roberto
Sabattini, Elena
Riminucci, Mara
Godio, Laura
Catani, Lucia
Nicolosi, Maura
Perricone, Margherita
Sollazzo, Daria
Colafigli, Gioia
Campana, Anna
Merli, Francesco
Vitolo, Umberto
Alimena, Giuliana
Martinelli, Giovanni
Lewis, Russell E.
Vianelli, Nicola
Cavo, Michele
Palandri, Francesca
2017
Details
Autor(en) / Beteiligte
Polverelli, Nicola
Breccia, Massimo
Benevolo, Giulia
Martino, Bruno
Tieghi, Alessia
Latagliata, Roberto
Sabattini, Elena
Riminucci, Mara
Godio, Laura
Catani, Lucia
Nicolosi, Maura
Perricone, Margherita
Sollazzo, Daria
Colafigli, Gioia
Campana, Anna
Merli, Francesco
Vitolo, Umberto
Alimena, Giuliana
Martinelli, Giovanni
Lewis, Russell E.
Vianelli, Nicola
Cavo, Michele
Palandri, Francesca
Titel
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
Ist Teil von
American journal of hematology, 2017-01, Vol.92 (1), p.37-41
Ort / Verlag
United States: Wiley Subscription Services, Inc
Erscheinungsjahr
2017
Link zum Volltext
Quelle
Wiley Online Library Journals Frontfile Complete
Beschreibungen/Notizen
Although infectious complications represent a relevant cause of morbidity and mortality in patients with myelofibrosis (MF), little is known about their incidence, outcome and risk factors. We retrospectively evaluated a cohort of 507 MF patients, diagnosed between 1980 and 2014 in five Italian hematology centers, to define the epidemiology of infections and describe the impact of ruxolitinib (RUX) treatment. Overall, 112 patients (22%) experienced 160 infectious events (grade 3–4, 45%) for an incidence rate of 3.9% per patient‐year. Infections were mainly bacterial (78%) and involving the respiratory tract (52% of cases). Also, viral (11%) and fungal infections (2%) were recorded. Overall, infections were fatal in 9% of the cases. Among baseline features, high/intermediate‐2 IPSS category (HR 1.8, 95%CI:1.2–2.7; P = 0.02) and spleen length ≥10 cm below left costal margin (HR 1.6, 95%CI:1.1–2.5; P = 0.04) were associated with higher infectious risk in multivariate analysis. Overall, the rate of infections was higher in the cohort of 128 RUX‐treated patients (44% vs. 20%, P < 0.001). In conclusion, IPSS‐category and splenomegaly, emerged as the main risk factors for infections in MF. RUX‐treated patients experienced significantly more infection episodes; however, future prospective studies are needed to isolate the confounding contribution of other risk factors such as disease stage. Am. J. Hematol. 92:37–41, 2017. © 2016 Wiley Periodicals, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0361-8609
eISSN: 1096-8652
DOI: 10.1002/ajh.24572
Titel-ID: cdi_proquest_journals_1850070859
Format
–
Schlagworte
Adult
,
Aged
,
Aged, 80 and over
,
Cohort Studies
,
Communicable Diseases - epidemiology
,
Communicable Diseases - etiology
,
Communicable Diseases - immunology
,
Female
,
Humans
,
Incidence
,
Infections
,
Janus Kinase 2 - antagonists & inhibitors
,
Janus Kinase 2 - genetics
,
Male
,
Middle Aged
,
Mortality
,
Primary Myelofibrosis - complications
,
Primary Myelofibrosis - drug therapy
,
Primary Myelofibrosis - epidemiology
,
Primary Myelofibrosis - immunology
,
Pyrazoles - administration & dosage
,
Pyrazoles - adverse effects
,
Pyrazoles - therapeutic use
,
Retrospective Studies
,
Risk Factors
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX